PTC Therapeutics (PTCT) Misses Q3 EPS by 69c

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.76), $0.69 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $196.58 million versus the consensus estimate of $210.19 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• CVG to join Russell 2000 and Russell 3000 indexes June 26